Expanded Access to TAK-881 for Children and Teenagers With Primary Immunodeficiency Diseases in the USA

Expanded Access Program for United States of America: TAK-881 Subcutaneous for the Treatment of Primary Immunodeficiency Diseases (PIDD)

NCT06955793•Takeda

View on ClinicalTrials.gov

AI summary by Clareo Health

Generating AI summary...

Conditions

Primary Immunodeficiency Diseases (PIDD)

Interventions

TAK-881

SC Investigational Needle Sets

Key Dates

Last Updated

May 2, 2025

Contacts

Takeda Contact

CONTACT

+1-877-825-3327 medinfoUS@takeda.com

Sponsors

Lead Sponsor

Takeda

Full Eligibility Criteria

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: May 2, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions